References
1. Fukuhara E. Mine T., Kishima H, Kitagaki R, Ishihara M. Increase in
Heart Rate-dependent Left Atrial Pressure is Associated with Symptoms in
Patients with Paroxysmal Atrial Fibrillation. J. Cardiovasc
Electrophysiol 2022 (In press)
2. Wynn GJ, Todd DM, Webber M, Bonnett L, McShane J, Kirchhof P, Gupta
D. The European Heart Rhythm Association symptom classification for
atrial fibrillation: validation and improvement through a simple
modification. Europace. 2014; 16:965-72.
3. Mitter SS, Shah SJ, Thomas JD. A test in context: E/A and E/e′ to
assess diastolic dysfunction and LV filling pressure. J Am Coll of
Cardiol. 2017; 69: 1451-64.
4. Rienstra M, Lubitz SA, Mahida S, Magnani JW, Fontes JD, Sinner MF,
Van Gelder IC, Ellinor PT, Benjamin EJ. Symptoms and functional status
of patients with atrial fibrillation: state of the art and future
research opportunities. Circulation. 2012; 125:2933-2943.
5. van den Berg MP, Hassink RJ, Tuinenburg AE, van Sonderen EF, Lefrandt
JD, de Kam PJ, van Gelder IC, Smit AJ, Sanderman R, Crijns HJ. Quality
of life in patients with paroxysmal atrial fibrillation and its
predictors: importance of the autonomic nervous system. Eur Heart J.
2001; 22:247-253.
8. Rho RW, Page RL. Asymptomatic atrial fibrillation. Progress in
cardiovascular diseases. 2005; 48:79-87.
9. Rienstra M, Vermond RA, Crijns HJ, Tijssen JG, Van Gelder IC, RACE
Investigators. Asymptomatic persistent atrial fibrillation and outcome:
results of the RACE study. Heart Rhythm. 2014; 11:939-945.
10. Gibbs H, Freedman B, Rosenqvist M, Virdone S, Al Mahmeed W, Ambrosio
G, Camm AJ, Jacobson B, Jerjes-Sanchez C, Kayani G, Oto A. Clinical
outcomes in asymptomatic and symptomatic atrial fibrillation
presentations in GARFIELD-AF: implications for AF screening. The
American Journal of Medicine. 2021; 134:893-901.
11. Bano A, Rodondi N, Beer JH, Moschovitis G, Kobza R, Aeschbacher S,
Baretella O, Muka T, Stettler C, Franco OH, Conte G. Association of
Diabetes With Atrial Fibrillation Phenotype and Cardiac and Neurological
Comorbidities: Insights From the Swiss‐AF Study. J Am Heart Assoc 2021;
10: e021800.
12. Noseworthy, P.A., Kaufman, E.S., Chen, L.Y., Chung, M.K., Elkind,
M.S., Joglar, J.A., Leal, M.A., McCabe, P.J., Pokorney, S.D., Yao.
Subclinical and device-detected atrial fibrillation: pondering the
knowledge gap: a scientific statement from the American Heart
Association. Circulation 2019; 140: e944-e963.
13. Quer G, Freedman B, Steinhubl SR. Screening for atrial fibrillation:
predicted sensitivity of short, intermittent electrocardiogram
recordings in an asymptomatic at-risk population. Europace. 2020;
22:1781-1787.
14. Kashou AH, Adedinsewo DA, Noseworthy PA. Subclinical Atrial
Fibrillation: A Silent Threat with Uncertain Implications. Annu Rev Med
2022; 73: 355-362.
15. Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L, Akar
JG, Badhwar V, Brugada J, Camm J, Chen PS. 2017
HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and
surgical ablation of atrial fibrillation. 2017; 14: e275-e433
16. ClinicaltTrials.gov Identifier: NCT01938248. The Apixaban for the
Reduction of Thrombo-Embolism in Patients with Device-Detected
Sub-Clinical Atrial Fibrillation (ARTESIA) trial
17. ClinicaltTrials.gov Identifier: NCT02618577. Non-vitamin K
Antagonist Oral Anticoagulants with Atrial High-Rate Episodes (NOAH).
18. Ding WY, Mandrola J, Gupta D. Left atrial appendage occlusion: past,
present and future. Thrombosis and Haemostasis. 2020; 120:1484-1491.